This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
ICOTYDE™ (icotrokinra)
Medical Information
Dosage and Administration Per Protocol in Phase 3 Plaque Psoriasis Trials
Last Updated: 03/18/2026
SUMMARY
- The company cannot recommend any practices, procedures, or usage of ICOTYDE that deviate from the approved labeling.
- Please refer to the local labeling for relevant information regarding dosage and administration of ICOTYDE.
- The administration and fasting requirements of ICOTYDE are described in the protocols for the ICONIC-LEAD, ICONIC-TOTAL, ICONIC-ADVANCE 1, and ICONIC-ADVANCE 2 phase 3 clinical trials.1
- 3
protocol Information
ICONIC-LEAD, ICONIC-TOTAL, ICONIC-ADVANCE 1 and ICONIC-ADVANCE 2 are phase 3, multicenter, randomized controlled trials that evaluated the safety and efficacy of ICOTYDE in patients with moderate to severe plaque PsO.1-3
Administration and Fasting Requirements
Patients were instructed to take a single 200 mg tablet (swallowed whole) with 240 mL (8oz) of water at approximately the same time every day upon waking on an empty stomach. Patients were advised not to eat food for at least 2 hours before and for at least 30 minutes after administration.1-3 For adolescents with difficulty swallowing, tablets could be suspended in a glass of water and fully taken within 15 minutes.1,
Literature Search
A literature search of MEDLINE®
References
| 1 | Bissonnette R, Soung J, Hebert AA, et al. Protocol to: Oral icotrokinra for plaque psoriasis in adults and adolescents. NEJM. 2025;393(18):1784-1795. |
| 2 | |
| 3 |